Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 0.71 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.60 |
| ▸ | PDE8A | O60658 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | CASR | P41180 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134904 | 0.92 | PDE7A (0.74) | PDE7APDE7BPDE8AMAPTKMT2A | |
| SCHEMBL100074 | 0.87 | PDE7A (0.91) | PDE7APDE7BPDE8AMAPTKMT2A | |
| SCHEMBL99998 | 0.86 | PDE7A (0.88) | PDE7APDE7BPDE8AMAPTKMT2A | |
| SCHEMBL30837831 | 0.84 | PDE7A (0.83) | PDE7APDE7BPDE8AMAPTKMT2A | |
| SCHEMBL100713 | 0.84 | PDE7A (0.83) | PDE7APDE7BPDE8AMAPTKMT2A | |
| SCHEMBL100698 | 0.83 | PDE7A (1.00) | PDE7APDE7BPDE8AMAPTKMT2A | |
| SCHEMBL30837972 | 0.83 | PDE7A (1.00) | PDE7APDE7BPDE8AMAPTKMT2A | |
| SCHEMBL100861 | 0.82 | PDE7A (0.84) | PDE7APDE7BPDE8AMAPTKMT2A | |
| SCHEMBL100754 | 0.81 | PDE7A (0.83) | PDE7APDE7BPDE8AMAPTKMT2A | |
| SCHEMBL30837899 | 0.81 | PDE7A (0.83) | PDE7APDE7BPDE8AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748441-B2 | Therapeutic uses of quinazolinedione derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748441-B2 | Therapeutic uses of quinazolinedione derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SLC5A2, SLC5A1, PPARD | PDE7A 1520/4885PDE7B 1364/4885PDE8A 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.